Royalty Pharma Q2 2026 earnings: Royalty receipts rise 14% as guidance increases

Royalty Pharma (Nasdaq: RPRX) reported Q2 2026 total income and other revenues of $674 million, up about 16% from $579 million a year earlier, while net income attributable to Royalty Pharma declined to $18 million from $32 million. Royalty Receipts increased 14%, and lower operating and development-stage funding payments helped GAAP operating cash flow double to $728 million. The quarter ended June 30, 2026, and the results were released on August 5.

Core financial results

The quarter showed a divergence between Royalty Pharma’s cash-based portfolio metrics and its GAAP earnings. Portfolio Receipts rose 6%, supported by higher royalties from several commercial therapies, but GAAP operating income fell because the provision for changes in expected cash flows from financial royalty assets shifted to a $268 million expense from a $204 million benefit.

Cash generation improved more substantially. Payments for operating and professional costs fell to $37 million from $94 million, while development-stage funding payments declined to $98 million from $301 million.

Portfolio Receipts represents Royalty Receipts plus milestones and other contractual receipts. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures defined under the company’s credit agreement rather than conventional profitability measures.

Business and portfolio performance

The commercial portfolio’s growth was led by Tremfya, Voranigo, Evrysdi and the new contribution from Imdelltra. Evrysdi’s increase included royalties acquired in December 2025, while Promacta declined because of U.S. generic competition.

The cystic fibrosis franchise remained the largest individual source of receipts at $194 million, or about one-quarter of total Portfolio Receipts, but was unchanged from the prior-year quarter. Milestones and other contractual receipts dropped to $5 million because the comparison period included a one-time distribution, explaining why Portfolio Receipts grew more slowly than Royalty Receipts.

Royalty Pharma deployed $349 million of capital during the quarter, primarily for daraxonrasib royalty funding and research and development funding for JNJ-4804 and litifilimab. First-half Capital Deployment totaled $877 million, compared with $696 million a year earlier.

As of August 4, announced transactions totaled up to $1.7 billion and Capital Deployment had reached $1.1 billion for 2026. In July, the company agreed to pay up to $425 million, including $125 million upfront, for part of Neurimmune’s royalty interest in AstraZeneca’s Phase 3 cliramitug. That transaction increased Royalty Pharma’s development-stage portfolio to 19 potential therapies.

Portfolio-related regulatory developments included FDA and European review progress for daraxonrasib, first-line metastatic triple-negative breast cancer approvals for Trodelvy, FDA approval of Jideytro for certain ROS1-positive lung cancers and European approval of Imdelltra for extensive-stage small cell lung cancer.

Cash generation improved while GAAP profit declined

The decline in GAAP earnings did not reflect weaker cash collections. Cash collections from financial royalty assets increased to $815 million from $727 million, while operating and professional cost payments fell by $57 million. Adjusted EBITDA equaled about 95% of Portfolio Receipts, up from roughly 87% in the prior-year quarter, reflecting the lower cash cost base.

The main pressure on reported operating profit was the $472 million year-over-year swing in the provision for changes in expected cash flows from financial royalty assets. This more than offset lower research and development funding expense, which fell to $98 million from $301 million, and lower general and administrative expense.

Royalty Pharma ended June with $812 million in cash and cash equivalents and $9.2 billion of debt by principal value. The company repaid a $380 million term loan at maturity in July. During Q2, it repurchased approximately 0.9 million shares for $45 million and paid a quarterly dividend of $0.235 per share.

Full-year 2026 guidance

Royalty Pharma raised its Portfolio Receipts outlook for the second time in 2026. The new range’s midpoint is $3.45 billion, $62.5 million—or about 2%—above the previous midpoint, while the cost and interest assumptions were unchanged.

The Portfolio Receipts outlook incorporates expected Royalty Receipts growth of 7% to 10% and an estimated positive foreign-exchange contribution of approximately 1%. It excludes contributions from future transactions. Management expects about $175 million of interest payments in Q3 and a minimal amount in Q4, reflecting the July term-loan repayment and an assumption of no additional 2026 debt financing.

Recent insider transactions

The supplied insider data shows 479,458 shares purchased through 18 transactions and 566,964 shares sold through 13 transactions over the past six months. That represents net selling of 87,506 shares, equal to 0.30% of the 28.87 million total insider shares held.

The latest reported records were concentrated in officer sales and director stock awards. The transactions are presented objectively and do not by themselves indicate insiders’ views of the company’s prospects.

Risks investors should monitor

• Milestone volatility: Milestones and other contractual receipts fell 91% after the prior-year period benefited from a one-time distribution. Similar timing differences can cause Portfolio Receipts growth to diverge from underlying royalty growth.
• Product concentration and mature-asset declines: The cystic fibrosis franchise generated about one-quarter of quarterly Portfolio Receipts. Promacta fell 75% because of U.S. generic competition, while Imbruvica declined 16%.
• GAAP earnings volatility: Changes in estimated future cash flows from financial royalty assets can create large movements in provisions and reported operating income even when current-period cash collections are rising.
• Debt and capital-allocation demands: Debt principal totaled $9.2 billion at quarter-end, and full-year interest payments are projected at $350 million to $360 million. Royalty acquisitions, development funding, debt repayment and shareholder returns all compete for portfolio cash flow.
• Development and regulatory outcomes: The portfolio contains 19 development-stage therapies, making clinical and regulatory progress important to future portfolio expansion. The quarter’s updates were not uniformly positive, as Gilead discontinued a Phase 3 Trodelvy study in metastatic non-small cell lung cancer.

Summary

Royalty Pharma’s Q2 2026 results were defined by double-digit Royalty Receipts growth and improved cash generation, partly offset by lower milestone receipts and a sharp decline in GAAP profit caused by royalty-asset cash-flow provisions. The raised full-year outlook indicates greater confidence in the existing portfolio, while product concentration, declining mature therapies, development-stage outcomes and the company’s debt and deployment commitments remain the main areas to monitor.